Skip to main content
SpringerLink
Log in

Ibrutinib ± rituximab for MCL saves costs versus chemoimmunotherapy

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Ghosh N, et al. Treatment patterns among patients with mantle cell lymphoma and comparison of healthcare resource utilization and costs among relapsed/refractory patients treated with ibrutinib or chemoimmunotherapy: A real-world retrospective study. Clinical Therapeutics : 28 Jul 2021. Available from: URL: http://doi.org/10.1016/j.clinthera.2021.06.012

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ibrutinib ± rituximab for MCL saves costs versus chemoimmunotherapy. PharmacoEcon Outcomes News 885, 12 (2021). https://doi.org/10.1007/s40274-021-07954-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-07954-x

Search

Navigation